Effects of atorvastatin and acipimox on the lipid spectrum of blood plasma, endothelial function and a clinical course of unstable angina pectoris

Terapevticheskii Arkhiv

Volumn 78, Issue 8, 2006, Pages 38-41

  Kurbanov, R D ^a   Shek, A B ^a   Tashkenbaeva, N F ^a  

^a NONE

Author keywords

Acipimox; Atorvastatin; The disease outcomes; Unstable angina pectoris

Indexed keywords

ACIPIMOX; ANTILIPEMIC AGENT; ATORVASTATIN; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PYRAZINE DERIVATIVE; PYRROLE DERIVATIVE;

ARTICLE; BLOOD; BRACHIAL ARTERY; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECT; FOLLOW UP; HUMAN; MALE; PATHOPHYSIOLOGY; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; VASCULAR ENDOTHELIUM; VASODILATATION;

ANGINA, UNSTABLE; ANTILIPEMIC AGENTS; BRACHIAL ARTERY; CHOLESTEROL, LDL; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PYRAZINES; PYRROLES; TREATMENT OUTCOME; VASODILATION;

EID: 33749031269     PISSN: 00403660     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Bellosta S., Bernini F., Ferry N. et al. Direct vascular effects of HMG-COA reductase inhibitors. Atherosclerosis 1998; 137: S101-S109.
2. Schwartz G. G., Olsson A. G., Ezekowitz M. D. et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: a randomized controlled trial. J. A. M. A. 2001; 285: 1711-1718.
3. Vaughan C. J., Murphy M. B., Buckley B. M. Statins do more, than lower cholesterol. Lancet 1996; 348: 1079-1082.
4. Taskinen M. R., Nikkila E. A. Effects of acipimox on serum lipids, lipoproteins and lipolytic enzymes in hypertriglyceridemia. Atherosclerosis 1988; 69: 249-255.